Concentrix: A Hidden Gem in AI Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy CNXC?
Source: Fool
- Positive Market Outlook: Concentrix achieved approximately 2% revenue growth in fiscal 2025 and anticipates a growth of 1.5% to 3% in fiscal 2026, indicating sustained demand for AI solutions and enhancing its competitive position in the market.
- Strong Cash Flow Performance: The company recorded an adjusted free cash flow of $626 million in fiscal 2025, with expectations to reach between $630 million and $650 million in fiscal 2026, providing funding for future investments while ensuring profitability enhancement.
- Analyst Ratings Favorable: About 75% of analysts rate Concentrix as a buy, with a median price target of $57 per share, suggesting a potential 33% return, reflecting strong market confidence in its future growth.
- Significant Valuation Advantage: Concentrix trades at just 10 times earnings and 3.6 times forward earnings, with a five-year PEG ratio of only 0.4, indicating its undervalued status, making it an attractive option among AI stocks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNXC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNXC
Wall Street analysts forecast CNXC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNXC is 57.33 USD with a low forecast of 54.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 37.460
Low
54.00
Averages
57.33
High
62.00
Current: 37.460
Low
54.00
Averages
57.33
High
62.00
About CNXC
Concentrix Corporation is a global technology and services company. The Company provides end-to-end capabilities, including customer experience (CX) process optimization, technology innovation, front- and back-office automation, analytics and business transformation. Its customer lifecycle management solutions include services such as customer care, sales support and digital marketing. It also provides complementary services, including CX/user experience (UX) strategy and design, digital transformation, and voice of the customer (VOC) and analytics. Its CX/UX strategy and design solutions, including CX strategy, data-driven user design, journey mapping, and multi-platform engineering. Its digital transformation solutions include services such as robotic process automation and cognitive automation and mobile app development. ConcentrixCX, its VOC solutions platform, helps turn customer feedback into actionable insights. It operates under the trade name Concentrix + Webhelp.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insider Stock Purchases Signal Confidence
- Insider Buying Signal: Concentrix CEO Christopher A. Caldwell purchased 1,000 shares of CNXC at $37.07 each on Thursday, totaling $37,070, indicating confidence in the company's future despite a 3.9% drop in stock price that day.
- Return Potential: Following the purchase, CNXC reached a trading high of $39.84, providing Caldwell with a potential return of 7.5% on his investment, reflecting positive market sentiment towards the stock.
- Historical Purchase Record: Over the past year, Caldwell has made five purchases of CNXC shares, totaling $262,841 at an average cost of $43.81 per share, demonstrating his ongoing confidence in the company's long-term prospects.
- Another Company’s Purchase: Parke Bancorp CEO Vito S. Pantilione also bought 1,000 shares of PKBK at $27.63 each on Thursday, totaling $27,630; while the stock remained flat that day, he saw a 4.4% return at the trading high.
See More
Concentrix: A Hidden Gem in AI Stocks
- Positive Market Outlook: Concentrix achieved approximately 2% revenue growth in fiscal 2025 and anticipates a growth of 1.5% to 3% in fiscal 2026, indicating sustained demand for AI solutions and enhancing its competitive position in the market.
- Strong Cash Flow Performance: The company recorded an adjusted free cash flow of $626 million in fiscal 2025, with expectations to reach between $630 million and $650 million in fiscal 2026, providing funding for future investments while ensuring profitability enhancement.
- Analyst Ratings Favorable: About 75% of analysts rate Concentrix as a buy, with a median price target of $57 per share, suggesting a potential 33% return, reflecting strong market confidence in its future growth.
- Significant Valuation Advantage: Concentrix trades at just 10 times earnings and 3.6 times forward earnings, with a five-year PEG ratio of only 0.4, indicating its undervalued status, making it an attractive option among AI stocks.
See More
Concentrix Achieves 'A' Score for Climate Change Leadership
- Climate Leadership Recognition: Concentrix earned an 'A' score from CDP in 2025, ranking in the top 2% among nearly 20,000 companies assessed globally, which enhances its reputation in sustainability and environmental responsibility.
- Emission Reduction Achievements: Since 2019, Concentrix has reduced CO₂ emissions by 27% and currently sources 35% of its power from renewable energy, aligning with its near-term targets and laying a solid foundation for future sustainability efforts.
- Tree Planting and Certification: In 2025, Concentrix marked the milestone of planting over one million trees and certifying more than half of its owned buildings to internal sustainability standards, demonstrating its commitment to environmental protection through tangible actions.
- Advancement of 2030 ESG Goals: The achievement of an 'A' rating signifies another step forward in Concentrix's sustainability journey, accelerating progress toward its 2030 Environmental, Social, and Governance (ESG) goals and reinforcing the company's commitment to responsible business practices.
See More
Concentrix (CNXC) Q4 2025 Earnings Call Transcript
See More
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
See More
Concentrix Corp (CNXC) Offers $1.44 Annual Dividend, Attracting Value Investors
- Dividend Appeal: Concentrix Corp offers an annual dividend of $1.44 per share, paid quarterly, attracting value investors' attention and indicating the company's strong performance in profitability and valuation.
- Importance of Dividend History: The report emphasizes that studying a company's past dividend history is crucial for assessing the likelihood of the latest dividend's continuation, providing investors with a basis for evaluating long-term stability and enhancing confidence in investment decisions.
- Investor Research Tool: Utilizing a proprietary DividendRank formula, the aim is to provide investors with a list of the most attractive stocks, helping them identify companies that excel in profitability and valuation, thereby optimizing their investment portfolios.
- Market Perspective: While the views expressed in the report do not necessarily reflect those of Nasdaq, Inc., they offer valuable insights for investors, highlighting the ongoing importance of high-dividend stocks and the need for continued research.
See More
Insider Stock Purchases Signal Confidence
- Insider Buying Signal: Concentrix CEO Christopher A. Caldwell purchased 1,000 shares of CNXC at $37.07 each on Thursday, totaling $37,070, indicating confidence in the company's future despite a 3.9% drop in stock price that day.
- Return Potential: Following the purchase, CNXC reached a trading high of $39.84, providing Caldwell with a potential return of 7.5% on his investment, reflecting positive market sentiment towards the stock.
- Historical Purchase Record: Over the past year, Caldwell has made five purchases of CNXC shares, totaling $262,841 at an average cost of $43.81 per share, demonstrating his ongoing confidence in the company's long-term prospects.
- Another Company’s Purchase: Parke Bancorp CEO Vito S. Pantilione also bought 1,000 shares of PKBK at $27.63 each on Thursday, totaling $27,630; while the stock remained flat that day, he saw a 4.4% return at the trading high.
See More
Concentrix: A Hidden Gem in AI Stocks
- Positive Market Outlook: Concentrix achieved approximately 2% revenue growth in fiscal 2025 and anticipates a growth of 1.5% to 3% in fiscal 2026, indicating sustained demand for AI solutions and enhancing its competitive position in the market.
- Strong Cash Flow Performance: The company recorded an adjusted free cash flow of $626 million in fiscal 2025, with expectations to reach between $630 million and $650 million in fiscal 2026, providing funding for future investments while ensuring profitability enhancement.
- Analyst Ratings Favorable: About 75% of analysts rate Concentrix as a buy, with a median price target of $57 per share, suggesting a potential 33% return, reflecting strong market confidence in its future growth.
- Significant Valuation Advantage: Concentrix trades at just 10 times earnings and 3.6 times forward earnings, with a five-year PEG ratio of only 0.4, indicating its undervalued status, making it an attractive option among AI stocks.
See More
Concentrix Achieves 'A' Score for Climate Change Leadership
- Climate Leadership Recognition: Concentrix earned an 'A' score from CDP in 2025, ranking in the top 2% among nearly 20,000 companies assessed globally, which enhances its reputation in sustainability and environmental responsibility.
- Emission Reduction Achievements: Since 2019, Concentrix has reduced CO₂ emissions by 27% and currently sources 35% of its power from renewable energy, aligning with its near-term targets and laying a solid foundation for future sustainability efforts.
- Tree Planting and Certification: In 2025, Concentrix marked the milestone of planting over one million trees and certifying more than half of its owned buildings to internal sustainability standards, demonstrating its commitment to environmental protection through tangible actions.
- Advancement of 2030 ESG Goals: The achievement of an 'A' rating signifies another step forward in Concentrix's sustainability journey, accelerating progress toward its 2030 Environmental, Social, and Governance (ESG) goals and reinforcing the company's commitment to responsible business practices.
See More
Concentrix (CNXC) Q4 2025 Earnings Call Transcript
See More
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
See More
Concentrix Corp (CNXC) Offers $1.44 Annual Dividend, Attracting Value Investors
- Dividend Appeal: Concentrix Corp offers an annual dividend of $1.44 per share, paid quarterly, attracting value investors' attention and indicating the company's strong performance in profitability and valuation.
- Importance of Dividend History: The report emphasizes that studying a company's past dividend history is crucial for assessing the likelihood of the latest dividend's continuation, providing investors with a basis for evaluating long-term stability and enhancing confidence in investment decisions.
- Investor Research Tool: Utilizing a proprietary DividendRank formula, the aim is to provide investors with a list of the most attractive stocks, helping them identify companies that excel in profitability and valuation, thereby optimizing their investment portfolios.
- Market Perspective: While the views expressed in the report do not necessarily reflect those of Nasdaq, Inc., they offer valuable insights for investors, highlighting the ongoing importance of high-dividend stocks and the need for continued research.
See More
